1st and only HAE treatment indicated for use in pediatrics. Learn more ►
Patient and professional support–on demand.

With help from Berinert Expert Network (B.E.N.®), you save administration time and make access to treatment easy for you and your patients.

Call B.E.N. now at
1-877-BEN-4HAE (1-877-236-4423)
Monday – Friday, 8 am to 8 pm ET

Patient and Professional Support Services Welcome to the Berinert Expert Network (B.E.N.®), a comprehensive assistance resource center for health care providers and their patients who depend on Berinert.

Our friendly and knowledgeable staff can answer many of your questions. They manage product-related information, connect you to CSL Behring service departments, and assist with enrollment in CSL Behring's support programs.

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Starting a patient on Berinert

Starting a new patient on Berinert is an easy process, and our B.E.N. Care Coordinators can guide you and your staff the entire way.

After downloading the form, fill it out and fax it to B.E.N. at 866-415-2162. If you have any questions while completing the Berinert referral form, please contact your local CSL Behring representative, or call B.E.N. at 877-236-4423. This form starts the process to get Berinert into the hands of the patient and enrolls the patient into the B.E.N. program. A B.E.N. Care Coordinator will be in touch with your office if any additional information is required or any clarification from the patient is necessary.

The B.E.N. Care Coordinators will work quickly to secure insurance approval for the patient and to partner with a specialty pharmacy to provide product and support.

Time-saving services for your practice

Trust us. Our B.E.N. Care Coordinators are experienced in helping physicians and their patients access everything Berinert has to offer. They’ll manage product-related information, connect you to CSL Behring service departments, and assist with enrollment in CSL Behring's support programs, including:

  • Starting a patient on Berinert
  • Insurance coverage, verification, and appeals
  • Access to Berinert patient financial assistance programs
  • Coding and billing assistance
  • Authorized distributor information
  • Information about HAE
  • Connection to the US Hereditary Angioedema Association (HAEA)

Value-added assistance programs for patients

Save up to $12,000 in co-pays with the
Berinert Co-Pay BENefit™

Living with hereditary angioedema (HAE) can be a heavy burden to bear. But it shouldn’t also be a financial burden. Help your patients take control of their HAE attacks and the cost of treatment. The Berinert Co-Pay BENefit* is a financial assistance program designed to cover their eligible out-of-pocket co-pay expenses— up to $12,000 per year.

Defend against loss of insurance with
CSL Behring AssuranceSM

A gap in insurance shouldn’t mean a gap in treatment. CSL Behring Assurance program is designed to help ensure that people who rely on Berinert can continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Assist patients with financial need through the Patient Assistance program

To help ensure that patients receive the treatment they need, the Patient Assistance program provides medically necessary therapy to qualified individuals who are uninsured, underinsured, or unable to afford their prescribed therapy.

Connect your HAE patients with
their peers

B.E.N. P.A.L.S.® (Peer Advocates for Learning and Support) are patients who have experience with HAE and treatment with Berinert. They can offer encouragement, assistance, and advice to your patients who have been recently diagnosed with HAE or whom you are starting with Berinert.

*The Berinert Co-Pay BENefit is available for new or existing Berinert patients. Patients MUST be 12 years of age or older, a U.S. resident, and insured in the U.S. Patients covered by state- or federally funded programs, such as Medicare, Medicaid, and Veterans Health Insurance, are NOT eligible.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »

Learn about Berinert availability, reimbursement information, diagnosis and product codes.

Home Support Services

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established.

BERINERT is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of BERINERT and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Appropriately trained patients may self-administer BERINERT upon recognition of an HAE attack. Advise patients to seek medical attention immediately following selfadministration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of BERINERT.

BERINERT is derived from human plasma. The risk of transmission of infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

BERINERT has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. In clinical trials, the half-life of BERINERT was shorter and clearance was faster in children than in adults; the clinical implication of this difference is not known.

Please see full prescribing information for BERINERT, including the patient product information.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d